Advances in the Understanding and Treatment of Nonalcoholic Fatty Liver Disease

Drugs

Volumn 63, Issue 22, 2003, Pages 2379-2394

  Harrison, Stephen A ^a   Di Bisceglie, Adrian M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ANTIOXIDANT; APOPTOSIS INHIBITOR; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BETAINE; CD4 ANTIGEN; CLOFIBRATE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; LEPTIN; LIVER ENZYME; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIOGLITAZONE; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TOCOPHEROL; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

CHRONIC LIVER DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME ASSAY; EVIDENCE BASED MEDICINE; FATTY ACID METABOLISM; FATTY LIVER; FIBROSIS; FUTUROLOGY; GLUCOSE METABOLISM; HISTOPATHOLOGY; HISTORY OF MEDICINE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER FAILURE; MEDICAL RESEARCH; NECROSIS; NONALCOHOLIC FATTY LIVER DISEASE; OBESITY; OXIDATIVE STRESS; PHLEBOTOMY; PROSPECTIVE STUDY; REVIEW; STEATOSIS; SYMPTOMATOLOGY; UNITED STATES;

ANTIOXIDANTS; CHRONIC DISEASE; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS;

EID: 0242524659     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363220-00001     Document Type: Review

References (140)

1. Westwater JO, Fainer D. Liver impairment in the obese. Gastroenterology 1958; 34: 686-93
2. Peters RL, Gay T, Reynolds TB. Post-jejunoileal bypass hepatic disease: its similarity to alcoholic hepatic disease. Am J Clin Pathol 1975; 63 (3): 318-31
3. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979; 67: 811-6
4. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8
5. Teli MR, James OFW, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-9
6. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9
7. Lee RG. Nonalcoholic steatohepatitis: a study of 39 patients. Hum Pathol 1989; 20: 594-8
8. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80
9. Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-9
10. Harrison SA, Torgerson S, Hayashi P. Natural history of NASH: a clinical histopathologic study. Am J Gastroenterol 2003; 98: 2042-7
11. Willner IR, Waters B, Raj Patil S, et al. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001; 96: 2957-61
12. Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplant for cryptogenic cirrhosis. Liver Transplant 2001; 7: 363-73
13. Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001; 7: 797-801
14. Shimada M, Hashimoto E, Taniai M, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002; 37: 154-60
15. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40
16. Ong JP, Younossi ZM. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? Gastroenterology 2002; 123: 375-8
17. Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635-43
18. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care 2001; 24: 1936-40
19. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288: 1723-7
20. National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey 1988-1994. Vol. I. Vital Health Statistics. Hyattsville (MD): National Center for Health Statistics, 1994
21. Harrison SA, Diehl AM. Fat and the liver: a molecular overview. Semin Gastrointest Dis 2002; 13 (1): 3-16
22. Nomura H, Kashiwagi S, Hayashi J, et al. Prevalence of fatty liver in the general population of Okinowa, Japan. Jpn J Med 1988; 27: 142-9
23. Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dyonisos study. Hepatology 1994; 20: 1442-9
24. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-57
25. Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002; 35: 746-52
26. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10
27. Garcia-Monson C, Martin-Perez E, Iacono OL, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000; 33: 716-24
28. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100
29. Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children: ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997; 42: 1428-32
30. Tominaga K, Kurata JH, Chen YK, et al. Prevalence of fatty liver in Japanese children and relationship to obesity: an epidemiological ultrasonographic survey. Dig Dis Sci 1995; 40: 2002-9
31. Manton ND, Lipsett J, Moore DJ, et al. Non-alcoholic steatohepatitis in children and adolescents. Med J Aust 2000; 173: 476-9
32. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-30
33. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 137-45
34. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-23
35. Harrison SA, Hayashi P. Clinical factors associated with fibrosis in 102 patients with nonalcoholic steatohepatitis [abstract]. Hepatology 2002; 36: 412A
36. Chitturi S, Weltman M, Farrell GC, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002; 36: 142-9
37. Santos L, Molina EG, Jeffers L, et al. Prevalence of nonalcoholic steatohepatitis among ethnic groups [abstract]. Gastroenterology 2001; 120: A117
38. Caldwell SH, Harris DM, Patrie JT, et al. Is NASH underdiagnosed among African-Americans. Am J Gastroenterol 2002; 97: 1496-500
39. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62
40. Youssef W, McCullough AJ. Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis 2002; 13: 17-30
41. Reaven G. Syndrome X: 10 years after [discussion appears in Drugs 1999; 58 Suppl. 1: 75-82]. Drugs 1999; 58 Suppl. 1: 19-20
42. DeFronso RA, Ferranini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94
43. Marchesini G, Brizi M, Marsell-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-5
44. Sanyal AJ, Campbell-Sargent C, Mirshani F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92
45. Pagano G, Pacini G, Musso G, et al. Non-alcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35: 367-72
46. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with insulin resistance syndrome. Hepatology 2002; 35: 373-9
47. Marceau P, Biron S, Hould FS, et al. Liver pathology and metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513-7
48. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-8
49. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 421-9
50. Younossi ZM, Gramlich T, Bacon BR, et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999; 30: 847-50
51. Mendler M-H, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1155-63
52. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 931-9
53. Graif M, Yanuka M, Baraz M, et al. Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease. Invest Radiol 2000; 35: 319-24
54. Saadeh S, Zobair M, Younossi ZM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50
55. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 1999; 94: 2468-73
56. Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial abnormalities in NASH. J Hepatology 1999; 31: 430-4
57. Day C, James O. Steatohepatitis: a tale of two "hits"? [editorial]. Gastroenterology 1998; 114: 842-5
58. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002; 109: 1345-50
59. Seppala-Lindroos A, Vehkavaara S, Hakkinen A-M, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 3023-8
60. Garg A, Misra A. Hepatic steatosis, insulin resistance, and adipose tissue disorders. Clin Endocrinol Metab 2002; 87: 3019-22
61. Kaplan LM. Leptin, obesity, and liver disease. Gastroenterology 1998; 115: 997-1001
62. Rutter GA. Diabetes: the importance of the liver. Curr Biol 2000; 10: R736-8
63. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001; 414: 799-806
64. Hug C, Lodish HF. Diabetes, obesity and acrp30/adiponectin. Biotechniques 2002; 33: 654-62
65. Zierath JR, Krook A, Wallberg-Henriksson H. Insulin action and insulin resistance in skeletal muscle. Diabetologia 2000; 43: 677-83
66. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-31
67. Cummings MH, Watts GF, Umpleby AM, et al. Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetes 1995; 44: 1059-65
68. Charlton M, Sreekumar R, Rasmussen D, et al. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002; 35: 898-904
69. Kim JK, Fillmore JJ, Chen Y, et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 2001; 98: 7522-7
70. Sun Z, Arendt CW, Ellmeier W, et al. PKC-theta is required for TCR-induced NF-κB activation in mature but not immature T lymphocytes. Nature 2000; 404: 402-7
71. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of IKKβ. Science 2001; 293: 1673-7
72. Mensenkamp AR, van Luyn MJA, van Goor H, et al. Hepatic lipid accumulation, altered very low density lipoprotein formation and apolipoprotein E deposition in apolipoprotein E3-Leiden transgenic mice. J Hepatol 2000; 33: 189-98
73. Bernard S, Touzet S, Personne I, et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 2000; 43: 995-9
74. Bjorkegren J, Beigneux A, Bergo MO, et al. Blocking the secretion of hepatic very low density lipoproteins renders the liver more susceptible to toxin-induced injury. J Biol Chem 2002; 277: 5476-83
75. Ceddia RB, Koistinen HA, Zierath JR, et al. Analysis of paradoxical observations on the association between leptin and insulin resistance. FASEB J 2002; 16: 1163-76
76. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive leptin concentrations in normal weight and obese humans. N Engl J Med 1996; 334: 292-5
77. Uygun A, Kadayifci A, Yesilova Z, et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000; 95: 3584-9
78. Reitman ML, Arioglu E, Gavrilova O, et al. Lipoatrophy revisited. Trends Endocrinol Metab 2000; 11: 410-6
79. Barzilai N, Wang J, Massilon D, et al. Leptin selectively decreases visceral adiposity and enhances insulin action. J Clin Invest 1997; 100: 3105-10
80. Sahu A. Resistance to the satiety action of leptin following chronic central leptin infusion is associated with the development of leptin resistance in neuropeptide Y neurons. J Neuroendocrinol 2002; 14: 796-804
81. Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 1996; 271: 665-8
82. Zanger R, Novak R. Effects of fatty acids and ketone bodies on cytochromes p4502B, 4A, 2E1 expression in primary cultured rat hepatocytes. Arch Biochem Biophys 1997; 337: 217-24
83. Leclercq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-75
84. Weltman MD, Farrell GC, Hall P. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-33
85. Pessayre D, Berson A, Fromenty B, et al. Mitochondria in steatohepatitis. Semin Liver Dis 2001; 21: 57-69
86. Rao MS, Reddy JK. Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis 2001; 21: 43-55
87. Baeuerle PA, Henkel T. Function and activation of NF-kB in the immune system. Annu Rev Immunol 1994; 12: 141-79
88. Crespo J, Cayon A, Fernadez-Gil P, et al. Gene expression of TNF-α and TNF receptors, p55 and p75. J Hepatol 2001; 34: 1158-63
89. Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. FASEB J 1998; 12: 57-65
90. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: implications for pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997; 94: 2557-62
91. Yang S, Zhu H, Li Y, et al. Mitochondrial adaptations to obesity-related oxidative stress. Arch Biochem Biophys 2000; 378: 259-68
92. Acosta D, Wenzel DG. Injury produced by free fatty acids to lysosomes and mitochondria in cultured heart muscle and endothelial cells. Atherosclerosis 1974; 20: 417-26
93. Chavin KD, Yang SQ, Lin HZ, et al. Obesity induces expression of UCP-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999; 274: 5692-700
94. Baffy G, Zhang C-Y, Glickman JN, et al. Obesity-related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2. Hepatology 2002; 35: 753-61
95. Cortez-Pinto H, Chatham J, Chacko V, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999; 282: 1659-64
96. Diehl AM. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol 2002; 282: G1-5
97. Li Z, Lin H, Yang S, et al. Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. Gastroenterology 2002; 123: 1304-10
98. Matsui K, Yoshimoto T, Tsutsui H, et al. Propionibacterium acnes treatment diminishes CD4+ NK1.1+ T cells but induces type I T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. J Immunol 1997; 159: 97-106
99. Friedman SL. The cellular basis of hepatic fibrosis: mechanisms and treatment strategies. N Engl J Med 1993; 328: 1828-33
100. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001; 35: 297-306
101. Nieto N, Friedman SL, Greenwel P, et al. CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells. Hepatology 1999; 30: 987-96
102. Svegliati-Baroni G, Saccomanno S, van Goor H, et al. Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells. Liver 2001; 21: 1-12
103. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999; 19: 129-40
104. Leclercq IA, Farrell GC, Schriemer R, et al. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002; 37: 206-13
105. Saxena NK, Ikeda K, Rockey DC, et al. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002; 35: 762-71
106. Ikejima K, Yoshiyuki T, Honda H, et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002; 122: 1399-410
107. Ueno T, Sagawara H, Sujaka K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-7
108. Drenick EJ, Simmons F, Murphy J. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets, and small bowel bypass. N Engl J Med 1970; 282: 829-34
109. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408-13
110. Harrison SA, Ramrakhiani S, Brunt EM, et al. Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 2003; 98: 926-30
111. Harrison SA, Fincke C, Helinski D, et al. Orlistat treatment in obese, non-alcoholic patients: a pilot study [abstract]. Hepatology 2002; 36: 406A
112. Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519-25
113. Neuschwander-Tetri BA, Brunt EM, Bacon BR. Histological improvement in NASH following reduction in insulin resistance with 48-week treatment with PPAR agonist rosiglitazone [abstract]. Hepatology 2002; 36: 379A
114. Nair S, Diehl AM, Perrillo R. Metformin in non alcoholic steatohepatitis (NASH): efficacy and safety: a preliminary report [abstract]. Gastroenterology 2002; 1222: A621
115. Marchesini G, Brizi M, Blanchi G, et al. Metformin in nonalcoholic steatohepatitis. Lancet 2001; 358: 893-4
116. Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C in the treatment of nonalcoholic steatohepatitis [abstract]. Gastroenterology 2002; 122: A669
117. Hasegawa T, Yoneda M, Nakamura K, et al. Plasma transforming growth factor-1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: 1667-72
118. Abdelmalek MF, Angulo P, Jorgensen RA, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96: 2711-7
119. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis [letter]. J Hepatol 1999; 31: 384
120. Laurin J, Lindor KD, Crippen JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-7
121. Horlander JC, Kwo PY, Cummings OW. Atorvastatin for the treatment of NASH [abstract]. Gastroenterology 2001; 120: A544
122. Ceriani R, Bunati S, Morini L, et al. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis [abstract]. Hepatology 1998; 28: 386A
123. Guma G, Viola L, Thome M, et al. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: results of a prospective clinical controlled trial [abstract]. Hepatology 1997; 26: 387A
124. Desai TK. Phlebotomy reduces transaminase levels in patients with non-alcoholic steatohepatitis [abstract]. Gastroenterology 2000; 118: A1071
125. Nitecki J, Jackson FW, Allen ML, et al. Effect of phlebotomy on non-alcoholic steatohepatitis (NASH) [abstract]. Gastroenterology 2000; 118: A6679
126. Lin HZ, Yang S, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6: 998-1003
127. Rozental P, Biava C, Spencer H, et al. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967; 12: 198-208
128. Anderson T, Gluud C, Franzmann MB, et al. Hepatic effects of dietary weight loss in morbidly obese patients. J Hepatol 1991; 12: 224-9
129. Despres J-P, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001; 322: 716-20
130. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000; 20: 270-9
131. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- acitivated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-6
132. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802
133. Fryer LGD, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002; 277: 25226-32
134. Kim Y-B, Ciaraldi TP, Kong A, et al. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110 protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes 2002; 51: 443-8
135. Galli A, Crabb DW, Cerri E, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002; 122: 1924-40
136. Musi N, Hirshman MF, Nygren J, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51: 2074-81
137. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-74
138. Lu SC. S-adenosylmethionine. Int J Biochem Cell Biol 2000; 32: 391-5
139. Mato JM, Camara J, Ortiz P, et al. Spanish collaborative group for the study of alcoholic liver cirrhosis. S-adenosylmethionine in the treatment of alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind mutlicentre clinical trial. J Hepatol 1999; 30: 1081-9
140. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001; 21: 81-8